Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

15.2%

5 terminated/withdrawn out of 33 trials

Success Rate

64.3%

-22.2% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

0 of 9 completed trials have results

Key Signals

13 recruiting

Enrollment Performance

Analytics

Phase 2

12(52.2%)

Phase 1

7(30.4%)

N/A

2(8.7%)

Early Phase 1

1(4.3%)

Phase 3

1(4.3%)

23Total

Phase 2(12)

Phase 1(7)

N/A(2)

Early Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (33)

Showing 20 of 33 trials

NCT04954599Phase 1Recruiting

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Role: collaborator

NCT02982694Phase 2Terminated

Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

Role: lead

NCT05385705Phase 1Terminated

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Role: lead

NCT07178717Phase 2Not Yet Recruiting

A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations

Role: lead

NCT04031872Phase 1Withdrawn

LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)

Role: collaborator

NCT03482362Phase 2Completed

Vinorelbine in Advanced BRAF-like Colon Cancer

Role: collaborator

NCT04832607Phase 3Recruiting

Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

Role: collaborator

NCT06385548Phase 1Withdrawn

Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer

Role: lead

NCT06630611Phase 2Recruiting

Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)

Role: lead

NCT06650514Phase 2Recruiting

A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma

Role: lead

NCT06411600Phase 2Recruiting

Combination Therapy for BRAF-V600E Metastatic CRCm

Role: lead

NCT06680739Phase 2Recruiting

Single cEll pRofiling PErsistaNce To ImmuNothErapy

Role: lead

NCT05141474Early Phase 1Recruiting

Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors

Role: lead

NCT03979131Phase 2Active Not Recruiting

Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)

Role: lead

NCT02819596Phase 2Completed

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma

Role: collaborator

NCT04019808Completed

Gastric Cancer Risk Factors Knowledge in European and Latinamerican Population

Role: collaborator

NCT06377267Phase 2Recruiting

Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)

Role: lead

NCT03957031Completed

Gastric Cancer Risk Factors Associated With EU and CELAC Populations